The absence of benefit was confirmed both during overall follow-up and in landmark 12-month analyses, with a reduction observed only in repeat revascularisation, a softer endpoint, and findings support an individualised approach to DAPT duration rather than routine prolongation beyond one year.
A. Gasca, N. Murillo, S. Cordoba et al.· European Heart Journal· 0 citations
GLP-1 receptor agonists reduce cardiovascular events in type 2 diabetes, but their role in heart failure with reduced ejection fraction (HFrEF) remains controversial due to concerns over heart rate elevation and potential arrhythmogenicity observed in prior trials.
To evaluate whether liraglutide added to...
R. R. Sabido, M. Lagunas, Y. Jiménez et al.· European Heart Journal· 0 citations
Rapid and sustained decongestion in acute heart failure with reduced ejection fraction (HFrEF) remains a therapeutic challenge, particularly in patients with diuretic resistance. Sequential nephron blockade with acetazolamide may enhance decongestion during hospitalization and, when continued intermittently after...
R. Sabido, S. Ramos, M. Lagunas et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.